GNI Group Ltd

3G6

Company Profile

  • Business description

    GNI Group Ltd is a clinical stage drug development company. It works on the treatment of diseases that are more common in Asia, especially Japan and China. It is engaged in the discovery, development, manufacture, and sale of drugs for the treatment of cancer and inflammatory diseases. The company's business activities are divided into the pharmaceutical business and the medical device business. In the pharmaceutical business, the company conducts research and development, manufacturing, and sales of development compounds, mainly I-Suru, which is sold in the Chinese market, and F351, which has completed clinical trials. In the medical device business, the company develops, manufacture, and sell medical devices (biomaterials) based in the United States.

  • Contact

    2-2-2 Nihonbashi Honcho
    3rd Floor, Nihonbashi Honcho YS Building
    Chuo-ku
    Tokyo103-0023
    JPN

    T: +81 362143600

    https://www.gnipharma.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    1,040

Stocks News & Analysis

stocks

ASX share undervalued despite solid growth

First-quarter performance exceeds expectations.
stocks

Chart of the Week: 3 undervalued US tech shares

Our US analysts’ top tech opportunities.
stocks

ASX payments utility looks overvalued

Australia’s invisible payments utility earns narrow moat yet valuation looks lofty.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,823.2071.40-0.80%
CAC 407,761.677.54-0.10%
DAX 4024,958.03146.33-0.58%
Dow JONES (US)51,145.8534.02-0.07%
FTSE 10010,496.3237.820.36%
HKSE23,785.79344.71-1.43%
NASDAQ27,393.42145.28-0.53%
Nikkei 22569,042.11993.60-1.42%
NZX 50 Index13,691.857.810.06%
S&P 5007,781.5520.22-0.26%
S&P/ASX 2008,660.9066.80-0.77%
SSE Composite Index3,811.9030.29-0.79%

Market Movers